Skip to main content

Table 1 Input parameters used in economic model

From: A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand

Parameter Distribution Mean SE Reference
Yearly discount rate (%)     
Costs and outcomes (range)   3 (0-6)   [51]
Transitional probability baseline parameters     
Probability of stable to CHB state Beta 0.143 0.0650 [31]
Probability of CHB to stable state Beta 0.056 0.0180 [32]
Probability of CHB to compensated in 1st-10th year Beta 0.054 0.0543 [33]
Probability of CHB to compensated in 11th-20th year Beta 0.134 0.1338 [33]
Probability of CHB to compensated in >20th year Beta 0.329 0.3292 [33]
Probability of CHB to HCC in 1st-5th year Beta 0.000 0.0000 [34]
Probability of CHB to HCC in 6th-10th year Beta 0.006 0.0061 [34]
Probability of CHB to HCC in >10th year Beta 0.008 0.0081 [34]
Probability of CHB to death in 1st-5th year Beta 0.010 0.0102 [34]
Probability of CHB to death in 6th-10th year Beta 0.014 0.0144 [34]
Probability of CHB to death in >10th year Beta 0.025 0.0252 [34]
Probability of compensated to decompensated in 1st-3rd year Normal 0.042 0.0003 [35]
Probability of compensated to decompensated in 4th-5th year Normal 0.094 0.0005 [35]
Probability of compensated to decompensated in >5th year Normal 0.066 0.0003 [35]
Probability of compensated to HCC in 1st-3rd year Normal 0.014 0.0002 [35]
Probability of compensated to in HCC 4th-5th year Normal 0.036 0.0003 [35]
Probability of compensated to HCC in >5th year Normal 0.030 0.0002 [35]
Probability of compensated to death in 1st-3rd year Beta 0.014 0.0135 [35]
Probability of compensated to death in >3rd year Beta 0.046 0.0461 [35]
Probability of decompensated to HCC Beta 0.035 0.0354 [36]
Probability of decompensated to death in 1st year Normal 0.260 0.0004 [37]
Probability of decompensated to death in 2nd year Normal 0.390 0.0005 [37]
Probability of decompensated to death in >2nd year Normal 0.240 0.0003 [37]
Probability of HCC to death in 1st year Beta 0.848 0.0011 [37]
Probability of HCC to death in >1st year Beta 0.920 0.0009 [37]
Transitional probability of treatment parameters     
Probability of CHB to compensated Beta 0.006 0.0023 [38]
Probability of CHB to HCC Beta 0.009 0.0045 [39]
Probability of CHB to death Beta 0.002 0.0023 [39]
Probability of compensated to HCC Beta 0.015 0.0034 [40]
Probability of compensated to death Beta 0.007 0.0070 [39]
Probability of decompensated to HCC Beta 0.035 0.0127 [41]
Probability of decompensated to death Beta 0.126 0.0291 [42]
Probability of compensated to CHB Beta 0.478 0.0665 [43]
Probability of HCC to death Beta 0.034 0.0227 [44]
Relative risk of seroconversion of lamivudine Normal 3.519 1.3707 [30]
Relative risk of seroconversion of adefovir Normal 3.028 1.3833 [30]
Relative risk of seroconversion of telbivudine Normal 4.286 1.4054 [30]
Relative risk of seroconversion of entecavir Normal 3.846 1.3833 [30]
Relative risk of seroconversion of pegylated interferon Normal 5.356 1.4987 [30]
Relative risk of seroconversion of tenofovir Normal 4.167 1.6403 [30]
Probability of delay seroconversion of pegylated interferon Normal 0.410 0.0489 [27]
Probability of lamivudine resistance Beta 0.214 0.0214 [28]
Probability of adefovir resistance Beta 0.066 0.0066 [28]
Probability of telbivudine resistance Beta 0.089 0.0089 [28]
Probability of entecavir resistance Beta 0.002 0.0002 [28]
Probability of tenofovir resistance Beta 0.000 0.0000 [28]
Annual direct medical cost     
Cost of generic lamivudine Gamma 1,797 180 [46]
Cost of original lamivudine Gamma 34,871 3,487 [46]
Cost of adefovir Gamma 70,298 7,030 [46]
Cost of telbivudine Gamma 51,504 5,150 [46]
Cost of entecavir Gamma 85,745 8,575 [46]
Cost of tenofovir Gamma 15,559 1,556 [46]
Cost of pegylated interferon Gamma 527,379 52,738 [46]
Cost of treatment of compensated cirrhosis Gamma 81,264 81,264 [48]
Cost of treatment of decompensated cirrhosis Gamma 125,127 125,127 [48]
Cost of treatment of HCC Gamma 153,021 153,021 [48]
Cost of laboratory for screening (i.e., HBeAg, HBeAb) Gamma 650 650 [47]
Cost of laboratory for pre-treatment Gamma 3,350 3,350 [47]
Cost of laboratory for monitoring Gamma 4,200 4,200 [47]
Cost of laboratory monitoring for pegylated interferon Gamma 10,620 10,620 [47]
Cost of laboratory monitor for adefovir Gamma 4,560 4,560 [47]
Cost of laboratory for post-treatment Gamma 4,900 4,900 [47]
Annual direct non-medical cost     
Cost of transportation Gamma 571 571 [54]
Cost of food Gamma 210 210 [54]
Annual indirect cost     
Cost of time loss due to receiving treatment Gamma 824 824 [49]
Cost of productivity loss of compensated cirrhosis Gamma 48 48 [48, 49]
Cost of productivity loss of decompensated cirrhosis Gamma 627 627 [48, 49]
Cost of productivity loss of HCC Gamma 1,701 1,701 [48, 49]
Utility     
Utility weight for CHB Normal 0.68 0.00005 [53]
Utility weight for compensated cirrhosis Normal 0.69 0.00016 [53]
Utility weight for decompensated cirrhosis Normal 0.35 0.00031 [53]
Utility weight for HCC Normal 0.38 0.00026 [53]